Priovant Therapeutics

News

Roviant & Priovant Therapeutics finally secure US approval for once-daily oral TYK2/JAK1 inhibitor, Lisraya (brepocitinib), for dermatomyositis.

News

Six months after Paul Chaplin said he was stepping down as CEO of Bavarian Nordic, the Danish biopharma has named Tarja Stenvall to the role.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.